DiaMedica Therapeutics (NASDAQ:DMAC) Given Buy Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of DiaMedica Therapeutics (NASDAQ:DMAC) in a report released on Thursday morning,Benzinga reports. They currently have a $10.00 target price on the stock.

DiaMedica Therapeutics Price Performance

NASDAQ:DMAC opened at $4.10 on Thursday. DiaMedica Therapeutics has a one year low of $2.14 and a one year high of $6.82. The company has a market cap of $175.82 million, a P/E ratio of -7.32 and a beta of 1.29. The firm’s fifty day moving average price is $3.89 and its two-hundred day moving average price is $4.98.

DiaMedica Therapeutics (NASDAQ:DMAC) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.18) EPS for the quarter, meeting the consensus estimate of ($0.18). During the same quarter last year, the company earned ($0.14) earnings per share. As a group, equities research analysts expect that DiaMedica Therapeutics will post -0.59 earnings per share for the current year.

Hedge Funds Weigh In On DiaMedica Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Paragon Associates & Paragon Associates II Joint Venture grew its stake in shares of DiaMedica Therapeutics by 6.7% in the fourth quarter. Paragon Associates & Paragon Associates II Joint Venture now owns 514,784 shares of the company’s stock valued at $2,795,000 after acquiring an additional 32,170 shares in the last quarter. Susquehanna International Group LLP grew its stake in shares of DiaMedica Therapeutics by 269.5% in the fourth quarter. Susquehanna International Group LLP now owns 374,845 shares of the company’s stock valued at $2,035,000 after acquiring an additional 273,395 shares in the last quarter. Northern Trust Corp grew its stake in shares of DiaMedica Therapeutics by 49.8% in the fourth quarter. Northern Trust Corp now owns 180,192 shares of the company’s stock valued at $978,000 after acquiring an additional 59,902 shares in the last quarter. Royal Bank of Canada grew its stake in shares of DiaMedica Therapeutics by 46,879.1% in the first quarter. Royal Bank of Canada now owns 155,031 shares of the company’s stock valued at $588,000 after acquiring an additional 154,701 shares in the last quarter. Finally, LPL Financial LLC grew its stake in shares of DiaMedica Therapeutics by 8.2% in the fourth quarter. LPL Financial LLC now owns 152,000 shares of the company’s stock valued at $825,000 after acquiring an additional 11,500 shares in the last quarter. 10.12% of the stock is currently owned by institutional investors and hedge funds.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.